You are here: Home › News › News archive › Genzyme looks to divestment and "multiyear action plan"

Genzyme looks to divestment and "multiyear action plan"

Genzyme plans to sell its businesses in diagnostics, genetics and drugs by year-end and formulate a "multiyear action plan" to boost financial results for 2011 and 2012.

Genzyme Chairman and CEO Henri Termeer said the second quarter was "difficult" for the company, having endured losses caused by contamination at its manufacturing plant in Allston, Mass.

Source: The Wall Street Journal

Document Actions

Send this

Navigation

Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...

Submit a news item!

News

Partners in the Cluster can submit news items to be circulated widely via the homepage of the Amsterdam BioMed Cluster.

Or add us to your mailing list for press releases: info[at]amsterdambiomed.nl

Personal tools

Genzyme looks to divestment and "multiyear action plan"

Document Actions

Penny-wise!

Find your life sciences partner in the Amsterdam BioMed Cluster